Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Top 3 Japan Generic Makers Face Uphill Struggle Overseas in April-September: Jiho Tally
November 25, 2021
- Japan Biz of Top 3 Generic Makers in H1 Impacted by GMP Issues, Substitution Demand: Jiho Tally
November 25, 2021
- Takeda’s CMV Drug Livtencity Bags US Approval
November 25, 2021
- Sosei Out-Licenses Neuropsychiatric Assets to Neurocrine
November 24, 2021
- Alnylam to File Its Third Drug in Japan 3 Years after Market Entry, Eyes CNS Therapies
November 24, 2021
- Top 4 Wholesalers’ Average Operating Margin at 0.46% on Tough Price Negotiations: H1 FY2021 Earnings
November 22, 2021
- Sales Reps’ Detailing Activities Rise 1.5% in September, but Remain in Doldrums: Intage
November 22, 2021
- Daiichi Sankyo Begins PIII for TROP2 ADC in Second-Line Breast Cancer
November 22, 2021
- Quizartinib Shows OS Benefit in Frontline AML, Daiichi Sankyo Mulls US/EU Filing
November 22, 2021
- Santen Signs Codevelopment Deal with Doshisha Univ. Startup for Sirolimus Eye Drop
November 19, 2021
- Bayer Yakuhin to Shutter Sales Offices for Better Efficiency and Productivity
November 19, 2021
- Daiichi Sankyo Begins PII for COVID-19 mRNA Vaccine, Eyes 2022 Rollout
November 18, 2021
- Otsuka’s Eczema Drug, 2 More Products Skip November Listing
November 18, 2021
- Aducanumab Gets “Negative Trend Vote” in Europe: Biogen/Eisai
November 18, 2021
- Chugai’s FoundationOne Approved to Identify TMB-High Solid Tumors as Keytruda CDx
November 18, 2021
- Opdivo Regains Top-Selling Title, Japan Pharma Market Grows 4.2% in July-September: IQVIA
November 17, 2021
- Astellas, Pantherna Link Arms on mRNA-Based Regenerative Medicine Research
November 16, 2021
- Kyowa Kirin’s Parkinson’s Med Rejected Again in Europe
November 16, 2021
- Kowa Files Livalo/Ezetimibe Fixed-Dose Combo in Japan
November 16, 2021
- Otsuka’s 9-Month Pharma Sales Up 0.8% on Double-Digit Growth of 4 Global Brands
November 16, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…